Fig. 5

Rheb1 deletion reduces mTORC1 signaling in AML cells. a FACS analysis of p-S6 in GFP⁺ cells. GFP⁺ cells were sorted from fresh BM cells. The left panel shows the mean fluorescent intensity (MFI) of both groups, the right panel shows the normalized MFI of these groups (n = 4). IgG was used as an internal control. b The normalized MFI of p-S6 in the LSC cells of the two groups (n = 4). c FACS analysis of p-4E-BP1 in GFP⁺ cells. GFP⁺ cells were sorted from fresh BM cells. The left panel shows the mean fluorescent intensity (MFI) of both groups, and the right panel shows the normalized MFI of these groups (n = 4). IgG was used as an internal control. d The normalized MFI of p-4E-BP1 in the LSC cells of the two groups (n = 4). e The percentage of apoptotic GFP⁺ cells treated with mock treatment (absolute ethanol without rapamycin, vehicle), and rapamycin was dissolved in absolute ethanol (EtOH) (n = 3). The data represent the mean numbers ± SEM. f The normalized MFI (Log10) of p-S6 in cultured GFP⁺ cells of the two groups treated with EtOH without rapamycin (n = 3). g The normalized MFI (Log10) of p-S6 in cultured GFP⁺ cells of the two groups treated with DMSO without 3BDO (n = 3). h The percentage of apoptotic GFP⁺ cells treated with mock treatment (DMSO without 3BDO, vehicle), and 3BDO was dissolved in DMSO (n = 3). i The Rheb1/mTORC1 signaling pathway in AML progression. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001